Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus

Table 2 Impact of clinical and genetic factors on partial response in HBeAg-negative chronic hepatitis B children

Characteristic	PR,	No-PR,	P value	OR (95%CI)
	n = 42	n = 10
Age (yr)
Median (range)	16 (4-18)	16 (5-18)	0.803
Gender
Female	14 (33.3)	2 (20.0)	0.412
Staging (F)
F0-F1	26 (61.9)	7 (70.0)	0.729
Grading (A)
A0-A1	20 (47.6)	5 (50.0)	0.892
Baseline HBV DNA (IU/mL)
Median (range), log	4.1 (3.4-8.0)	5.9 (3.6-8.0)	0.017
< 20000	28 (66.7)	3 (30.0)	0.069
Baseline ALT (U/L)
Median (range)	44 (10-120)	63 (22-118)	0.003
< 40	13 (31.0)	1 (10.0)	0.207
IL28B rs12979860
CC	19 (45.2)	1 (10.0)	0.068
CT	20 (47.6)	6 (60.0)
TT	3 (7.2)	3 (30.0)	0.077
IL28B rs12980275
AA	23 (54.8)	1 (10.0)	0.014	10.9 (1.3-93.9)
AG	17 (40.6)	7 (70.0)
GG	2 (4.8)	2 (20.0)	0.163
IL28B rs8099917
TT	27 (64.2)	3 (30.0)	0.075
TG	13 (31.0)	6 (60.0)
GG	2 (4.8)	1 (10.0)	0.481
OASL rs10849829
AA	16 (38.1)	5 (50.0)	0.500
AG	20 (47.6)	5 (50.0)
GG	6 (14.3)	0 (0.0)	0.582
OAS1 rs1131476
AA	19 (45.2)	7 (70.0)	0.291
AG	15 (35.7)	2 (20.0)
GG	8 (19.1)	1 (10.0)	0.670
OAS2 rs1293747
GG	25 (59.5)	7 (70.0)	0.481
GA	15 (35.7)	2 (20.0)
AA	2 (4.8)	1 (10.0)	0.722
OAS3 rs2072136
GG	23 (54.8)	7 (70.0)	1.000
GA	17 (40.6)	3 (30.0)
AA	2 (4.8)	0 (0.0)	0.488

Data are presented as the number of patients (%) unless otherwise indicated.